Polypharmacology in precision oncology: Current applications and future prospects

Current Pharmaceutical Design

Volumn 22, Issue 46, 2016, Pages 6935-6945

  Antolin, Albert A ^a,b   Workman, Paul ^a   Mestres, Jordi ^b   Al Lazikani, Bissan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Biomarker; Multi target drug design; Off target; Polypharmacology; Precision oncology; Side effects; Systems pharmacology; Target profiling

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CRIZOTINIB; IMATINIB;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOLOGY; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYPHARMACOLOGY; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; DRUG REPOSITIONING; DRUG RESISTANCE; NEOPLASM;

ANTINEOPLASTIC AGENTS; DRUG REPOSITIONING; DRUG RESISTANCE, NEOPLASM; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; POLYPHARMACOLOGY;

EID: 85012083434     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160923115828     Document Type: Review

References (125)

1. Greaves M. Evolutionary determinants of cancer. Cancer Discov 2015; 5(8): 806-21
2. Workman P, Al-Lazikani B, Clarke PA. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr Opin Pharmacol 2013; 13(4): 486-96
3. Workman P, Al-Lazikani B. Drugging cancer genomes. Nat Rev Drug Discov 2013; 12(12): 889-90
4. Chabner BA, Roberts TG. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5: 65-72
5. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136(5): 823-37
6. Weinstein IB. Addiction to oncogenes — the achilles heal of cancer. Science 2002; 297: 63-4
7. Patel MN, Halling-Brown MD, Tym JE, Workman P, Al-Lazikani B. Objective assessment of cancer genes for drug discovery. Nat Rev Drug Discov 2013; 12: 35-50
8. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012; 30(7): 679-92
9. Rubio-Perez C, Tamborero D, Schroeder MP, et al. In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities. Cancer Cell 2015; 27(3): 382-96
10. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013; 93(3): 252-9
11. Willyard C. Cancer therapy: an evolved approach. Nature 2016; 532(7598): 166-8
12. Kushner D. Playing dirty. IEEE Spectr 2007; 44(12): 32-7
13. Pérez-Nueno VI. Using quantitative systems pharmacology for novel drug discovery. Expert Opin Drug Discov 2015; 1-17
14. Wathieu H, Issa NT, Byers SW, Dakshanamurthy S. Harnessing polypharmacology with computer-aided drug design and systems biology. Curr Pharm Des 2016; 22(21): 3097-108
15. Jalencas X, Mestres J. On the origins of drug polypharmacology. MedChemComm 2012; 4: 80-7
16. Tang J, Aittokallio T. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Curr Pharm Des 2014; 20: 23-36
17. Maehle A, Prüll C, Halliwell RF. The emergence of the drug receptor theory. Nar Rev Drug Discov 2002; 1(8): 637-41
18. Peters JU. Polypharmacology Foe or friend? J Med Chem 2013; 56(22): 8955-71
19. Keiser MJ, Irwin JJ, Shoichet BK. The chemical basis of pharmacology. Biochemistry 2010; 49(48): 10267-76
20. Mestres J, Gregori-Puigjané E, Valverde S, Solé RV. Data completeness-the Achilles heel of drug-target networks. Nat Biotechnol 2008; 26(9): 983-4
21. Fabian MA, Biggs WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005; 23(3): 329-36
22. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3(4): 353-9
23. Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: A large-scale bioactivity database for drug discovery. Nucleic Acids Res 2012; 40(D1): 1100-7
24. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotechnol 2006; 24(7): 805-15
25. Yıldırım MA, Goh KI, Cusick ME, Barabási AL, Vidal M. Drug— target network. Nat Biotechnol 2007; 25(10): 1119-26
26. Pemovska T, Johnson E, Kontro M, et al. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 2015; 519(7541): 102-5
27. Ciceri P, Müller S, O’Mahony A, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 2014; 10(4): 305-12
28. Antolín AA, Mestres J. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget 2014; 5(10): 3023-8
29. Huang X-P, Karpiak J, Kroeze WK, et al. Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65. Nature 2015; 527(7579): 477-83
30. Chen X, Zhao C, Li X, et al. Terazosin activates Pgk1 and Hsp90 to promote stress resistance. Nat Chem Biol 2015; 11(1): 19-25
31. Flachner B, Lörincz Z, Carotti A, et al. A chemocentric approach to the identification of cancer targets. PLoS One 2012; 7(4): e35582
32. Garcia-Serna R, Vidal D, Remez N, Mestres J. Large-Scale predictive drug safety: from structural alerts to biological mechanisms. Chem Res Toxicol 2015; 28(10): 1875-87
33. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med 2012; 366(6): 489-91
34. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10(7): 514-23
35. Workman P. How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003; 9(11): 891-902
36. Frenel JS, Carreira S, Goodall J, et al. Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin Cancer Res 2015; 21(20): 4586-96
37. FDA Table of Pharmacogenomic Biomarkers in Drug Labeling. Available at: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm accessed 17th M 2016
38. Registry Database of Clinicals. Available at: clinicaltrials.gov
39. Red Brewer M, Pao W. Maximizing the benefits of off-target kinase inhibitor activity. Cancer Discov 2013; 3(2): 138-40
40. Tym JE, Mitsopoulos C, Coker EA, et al. CanSAR: An updated cancer research and drug discovery knowledgebase. Nucleic Acids Res 2014; 42(D1): 61-3
41. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1(7): 493-502
42. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293(5531): 876-80
43. Deininger MW. Nilotinib. Clin Cancer Res 2008; 14(13): 4027-31
44. Chase F, Veterans P, Medical A, Oncology N, OncolB. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347(7): 472-80
45. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347(7): 481-7
46. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128(2): 270-9
47. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007; 110(12): 4055-63
48. Bulusu KC, Tym JE, Coker EA, Schierz AC, Al-Lazikani B. CanSAR: Updated cancer research and drug discovery knowledgebase. Nucleic Acids Res 2014; 42: 1040-7
49. Shaw AT, Yasothan U, Kirkpatrick P. Crizotinib. Nat Rev Drug Discov 2011; 10: 897-8
50. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007; 67(9): 4408-17
51. Cui JJ, Tran-Dubé M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011; 54(18): 6342-63
52. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Iafrate AJ, Engelman JA. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Cancer Res 2012; 72(8): 5593-3
53. Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371(21): 1963-71
54. Bergethon K, Shaw AT, Ou SHI, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30(8): 863-70
55. Drilon A, Somwar R, Wagner JP, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin Cancer Res 2016; 22(10): 2351-8
56. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29(36): 4803-10
57. Yu HA, Pao W. Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer. Nat Rev Clin Oncol 2013; 10(10): 551-2
58. Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012; 133(3): 1057-65
59. Cortes J, Dieras V, Ro J, et al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, openlabel, multicentre, phase 2 tr. Lancet Oncol 2015; 16(16): 1700-10
60. Choudhury NJ, Campanile A, Antic T, et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol 2016; 34(18): 2165-71
61. Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: A potential mechanism of acquired resistance to egfr inhibition in EGFR -mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discov 2012; 2(10): 922-33
62. McCarthy N. Lung cancer: Overcoming crizotinib resistance. Nat Rev Cancer 2014; 14(5): 297
63. Subbiah V, Hong DS, Meric-Bernstam F. Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. Proc Natl Acad Sci USA 2016; 113(11): 1419-20
64. Toyokawa G, Inamasu E, Shimamatsu S, et al. Identification of a novel ALK G1123S mutation in a patient with ALK-rearranged non-small-cell lung cancer exhibiting resistance to ceritinib. J Thorac Oncol 2015; 10(7): 55-7
65. Blay JY, Shen L, Kang YK, et al. Nilotinib versus imatinib as firstline therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol 2015; 16(5): 550-60
66. Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, et al. Phase II study of nilotinib in melanoma harboring KIT alterations following progression to prior KIT inhibition. Clin Cancer Res 2015; 21(10): 2289-96
67. Hochhaus A, Saglio G. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013; 121(18): 3703-8
68. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012; 367(22): 2075-88
69. Kwak Y, Cho H, Hur W, Sim T. Antitumor effects and mechanisms of AZD4547 on FGFR2-deregulated endometrial cancer cells. Mol Cancer Ther 2015; 14(10): 2292-302
70. Borad M. Ponatinib hydrochloride in treating patients with advanced biliary cancer with FGFR2 fusions. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000-2016. Available from: URL of the record NLM Identifier: NCT02265341
71. Khodadoust MS, Luo B, Medeiros BC, et al. Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 2015; 1-4
72. Smith CC, Lasater EA, Zhu X, et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood 2013; 121(16): 3165-71
73. Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 2011; 10(6): 1028-35
74. De Falco V, Buonocore P, Muthu M, et al. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab 2013; 98(5): 811-9
75. Ou I. Ponatinib in Advanced NSCLC w/ RET Translocations. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 2000-2016. Available from: URL of the record NLM Identifier: NCT01813734
76. Radich J. Structure, function, and resistance in chronic myeloid leukemia. Cancer Cell 2014; 26(3): 305-6
77. Byron SA, Chen H, Wortmann A, et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia 2013; 15(8): 97588
78. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 2006; 5(9): 717-8
79. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011; 1(1): 78-89
80. Bristol-Myers Squibb. Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) 20002016. Available from: URL of the record NLM Identifier: NCT01514864
81. Pitini V, Arrigo C, Di Mirto C, Mondello P, Altavilla G. Response to dasatinib in a patient with SQCC of the lung harboring a discoidreceptor2 and synchronous chronic myelogenous leukemia. Lung Cancer 2013; 82(1): 171-2
82. Terai H, Tan L, Beauchamp EM, et al. Characterization of DDR2 inhibitors for the treatment of DDR2 mutated nonsmall cell lung cancer. ACS Chem Biol 2015; 10(12): 2687-96
83. Herold CI, Chadaram V, Peterson BL, et al. Phase II trial of dasatinib in patients with metastatic breast cancer using real-time pharmacodynamic tissue biomarkers of Src inhibition to escalate dosing. Clin Cancer Res 2011; 17(18): 6061-70
84. Perez M, Lucena-Cacace A, Marín-Gómez LM, et al. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget 2016; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27105527
85. Dowell J, Dowell J, Minna JD, Minna JD, Kirkpatrick P, Kirkpatrick P. Fresh from the Pipeline: Erlotinib hydrochloride. Nat Rev Drug Discov 2005; 4(1): 13-4
86. Li Z, Xu M, Xing S, et al. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem 2007; 282(6): 3428-32
87. Cherry M, Khawandanah M, Zhao ZJ, et al. Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Ann Hematol 2014; 94(4): 717-9
88. Propper D, Davidenko I, Bridgewater J, et al. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Ann Oncol 2014; 25(7): 1384-90
89. Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old drugs. AAPS J 2012; 14(4): 759-63
90. Bertolini F, Sukhatme VP, Bouche G. Drug repurposing in oncology— patient and health systems opportunities. Nat Rev Clin Oncol 2015; 12(12): 732-42
91. Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg Med Chem Lett 2009; 19(15): 4102-6
92. Antolin AA, Mestres J. Distant Polypharmacology among MLP Chemical Probes. ACS Chem Biol 2015; 10(2): 395-400
93. Off-patent Drugs Bill 2015-16. Available from: http://services.parliament.uk/bills/2015-16/offpatentdrugs.html
94. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6(9): 734-45
95. Joosten SC, Hamming L, Soetekouw PM, et al. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta Rev Cancer 2015; 1855(1): 1-16
96. Stewart GD, O’Mahony FC, Laird A, et al. Sunitinib treatment exacerbates intratumoral heterogeneity in metastatic renal cancer. Clin Cancer Res 2015; 21(18): 4212-23
97. Guo T, Hajdu M, Agaram NP, et al. Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KIT AY502-3ins mutation: An in vitro mutagenesis screen for drug resistance. Clin Cancer Res 2009; 15(22): 6862-70
98. Girotti MR, Lopes F, Preece N, et al. Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma. Cancer Cell 2015; 27(1): 85-96
99. Winter GE, Rix U, Carlson SM, et al. Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. Nat Chem Biol 2012; 8(11): 905-12
100. Hopkins AL. Drug discovery: Predicting promiscuity. Nature 2009; 462(7270): 167-8
101. Krejsa CM, Horvath D, Rogalski SL, et al. Predicting ADME properties and side effects: the BioPrint approach. Curr Opin Drug Discov Dev 2003; 6(4): 470-80
102. Jacoby QE, Tresadern G, Bembenek S, et al. Extending kinome coverage by analysis of kinase inhibitor broad profiling data. Drug Discov Today 2015; 20(6): 652-8
103. Knapp S, Arruda P, Blagg J, et al. A public-private partnership to unlock the untargeted kinome. Nat Chem Biol 2013; 9(1): 3-6
104. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009; 5(9): 616-24
105. Huber KVM, Salah E, Radic B, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 2014; 508(7495): 222-7
106. Dale T, Clarke PA, Esdar C, et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nat Chem Biol 2015; 11(12): 973-80
107. Molina DM, Jafari R, Ignatushchenko M, Seki T. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 2013; 341(7): 84-7
108. Almqvist H, Axelsson H, Jafari R, et al. CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil. Nat Commun 2016; 7: 11040
109. Schirle M, Jenkins JL. Identifying compound efficacy targets in phenotypic drug discovery. Drug Discov Today 2015; 21(1): 82-9
110. Koutsoukas A, Simms B, Kirchmair J, et al. From in silico target prediction to multi-target drug design: Current databases, methods and applications. J Proteomics 2011; 74(12): 2554-74
111. Keiser MJ, Setola V, Irwin JJ, et al. Predicting new molecular targets for known drugs. Nature 2009; 462(7270): 175-81
112. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 2007; 152(12): 9-20
113. Fonslow BR, Stein BD, Webb KJ, et al. Linking Pharmacology to Clinical Reports: Cyclobenzaprine and Its Possible Association With Serotonin Syndrome. Clin Pharmacol Ther 2013; 10(1): 54-6
114. Jalencas X, Mestres J. Chemoisosterism in the proteome. J Chem Inf Model 2013; 53(2): 279-92
115. Weber A, Casini A, Heine A, et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004; 47(3): 550-7
116. Iorio F, Bosotti R, Scacheri E, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A 2010; 107(33): 14621-6
117. Woo JH, Shimoni Y, Yang WS, et al. Elucidating compound mechanism of action by network perturbation analysis. Cell 2015; 162: 441-51
118. Seashore-Ludlow B, Rees MG, Cheah JH, et al. Harnessing connectivity in a large-scale small-molecule sensitivity dataset. Cancer Discov 2015; 5(11): 1210-23
119. Remez N, Garcia-serna R, Vidal D, Mestres J. The in vitro pharmacological profile of drugs as a proxy indicator of potential in vivo organ toxicities. Chem Res Toxicol 2016; 29(4): 637-48
120. Besnard J, Ruda GF, Setola V, et al. Automated design of ligands to polypharmacological profiles. Nature 2012; 492(7428): 215-20
121. Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol 2008; 4(11): 691-9
122. Wu L, Yu J, Chen R, et al. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently Inhibits the proliferation of imatinib-resistant CML cells. Clin Cancer Res 2015; 21: 833-43
123. Meng T, Zhang D, Xie Z, et al. Discovery and optimization of 4,5diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90. J Med Chem Chem 2014; 57(23): 9832-43
124. Qian C, Lai CJ, Bao R, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 2012; 18(15): 4104-13
125. Dar AC, Das TK, Shokat KM, Cagan RL. Chemical genetic discovery of targets and anti-targets for cancer polypharmacology. Nature 2012; 486(7401): 80-4